Baker McKenzie advised CatalYm, an innovative biotech company developing novel cancer immunotherapies, on the closing of its EUR 50 million Series B equity financing. The financing consortium led by lead investor Vesalius Biocapital III also includes Novartis Venture Fund (NVF), Wachstumsfonds Bayern, coparion and the founding investors Forbion and BioGeneration Ventures. Representatives of Vesalius, NVF and Wachstumsfonds Bayern will join the advisory board as new members.
The financing, combined with the strong commitment of existing and new institutional venture capital investors, will enable the important further development of antibodies in the field of immune-oncology.
A team of Baker McKenzie life sciences lawyers led by Julia Braun advised CatalYm on all legal aspects of the Series B equity financing.
"Especially the times of COVID-19 are a highly crucial phase for our client and the entire healthcare industry. Together with CatalYm and a team of lawyers of the firm specialized in the field of biotechnology, we were able to help CatalYm to successfully secure a significant funding for further R&D in the field of immune-oncology with this transaction", comments Julia Braun, Corporate/M&A counsel at Baker McKenzie, who led the transaction.
CatalYm is a biopharmaceutical company developing novel cancer immunotherapies targeting Growth-and-Differentiation Factor 15 (GDF-15). The Company was founded in 2016 as a spin-off from Wuerzburg University. CatalYm is led by a seasoned senior executive team with substantial I/O drug development as well as deal making experience and backed by international venture capital investors.
Baker McKenzie's Corporate / M&A and life science team regularly advises big pharma, financial investors and early stage biotech companies on domestic and international healthcare transactions. Most recently, Baker McKenzie advised, among others, Casdin Capital on a USD 50 million extension of the Series B Financing in DNA Script, Chr. Hansen Holding on the acquisition of Jennewein, CureVac on its strategic mRNA technology collaboration with GSK, LSP Life Science Partners on a USD 38.5 million Series B financing in DNA Script, Galapagos on its 10 year global research and development collaboration with Gilead, Hitachi Chemical Company, Tokyo on the take-over of German apceth Biopharma, Forbion as lead investor on a EUR 17 million Series C Equity Financing of Omeicos Therapeutics as well as on a USD 54 million Series A Equity Financing of Gotham Therapeutics Corporation and Mundipharma on the sale of its Limburg production.
Legal advisor to CatalYm:
Lead: Corporate/M&A: Julia Braun (counsel, Munich)
Team: Corporate/M&A: Berthold Hummel (partner, Munich), Michelle Karrer, Dr. Julia Rossié (both associate, Munich)
Public Law: Anahita Thoms (partner, Dusseldorf), Alexander Ehrle (associate, Berlin)
Antitrust & Trade: Dr. Christian Burholt (partner, Berlin), Dr. Jonas Brueckner (counsel, Berlin)